We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Clinical Updates

Malignancy Risk Patterns in Solid Organ Transplant Recipients with a History of Pretransplant Cancer

MedXY Editorial Team•Mar 15, 2026•Clinical Updates
immunosuppressiononcologytransplantationがんサバイバーシップ

Highlights

  • Solid organ transplant (SOT) recipients with a pretransplant cancer history have a significantly increased risk of developing the same type of cancer posttransplant.
  • The highest risk association was observed for melanoma, with an incidence rate ratio (IRR) of 10.4.
  • Specific cross-cancer associations exist, such as pretransplant kidney cancer increasing the risk of posttransplant thyroid cancer.
  • Risk levels for certain cancers (liver, kidney, lung) in SOT recipients were lower than standardized incidence ratios (SIRs) seen in cancer survivors in the general population, suggesting complex interactions between organ disease and immunosuppression.

Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Advancing Sentinel Lymph Node Biopsy in Vulvar Cancer: Real-Time Near-Infrared Fluorescence Imaging Enhances Detection and SafetyA recent study demonstrates the feasibility and safety of hybrid indocyanine green and technetium-99m nanoparticle fluorescence imaging for sentinel lymph node biopsy in early-stage vulvar cancer, improving detection rates and oncologic outSep 25, 2026HBV-Induced Immunosuppressive Macrophages: Metabolic and Epigenetic Pathways Driving Chronic Hepatitis B PersistenceThis article reviews recent evidence on how HBV manipulates monocyte-to-macrophage differentiation through metabolic and epigenetic reprogramming, facilitating immunosuppression and chronic infection.Sep 21, 2026Pembrolizumab Plus Chemotherapy for Cervical Cancer: Five-Year Exploratory Analysis from the KEYNOTE-826 Randomized Clinical TrialFive-year data from KEYNOTE-826 confirm pembrolizumab combined with chemotherapy as a durable, first-line treatment improving survival in persistent, recurrent, or metastatic cervical cancer without new safety concerns.Sep 15, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
HPV-Associated Anal Dysplasia in Solid Organ Transplant Recipients: Unraveling Transplant-Specific Mucosal Immune Dysfunction
Solid organ transplant recipients have increased risk of HPV-driven anal dysplasia and cancer due to unique immune alterations from immunosuppression. This article explores the transplant-specific immune dysfunction underlying persistent HP
Sep 5, 2026
Reevaluating Calcineurin Inhibitor Use in Identical Twin Kidney Transplants: Are We Overmedicating?Despite identical immunogenetic makeup, half of kidney transplant recipients from identical twins remain on calcineurin inhibitors, with no demonstrable benefit in rejection reduction or graft survival over 25 years, calling for critical reSep 4, 2026
Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and PatientsThis study examines the impact of biosimilar introduction on cancer biologics, highlighting reduced costs and market share for originator biologics, benefiting both payers and patients.Aug 29, 2026